RSS Feeds
Search

Companies

Companies

Displaying 1..10 of 15 - per page Next page
Order by
Palau Pharma
Palau Pharma is a product-driven biopharmaceutical company focused on the discovery and development of new medicines for the treatment of inflammatory and autoimmune diseases. More
Merck KGaA
Focus is on innovations in pharmaceuticals and chemicals More
Jelfa Pharmaceutical Company
Production, distribution and marketing of solid, semi-solid and injectable preparations. More
RAFARM
Development & Marketing of Pharmaceuticals for Human Use More
Biomedica Foscama
Biomedica Foscama is committed in development, production and marketing of prescription pharmaceuticals. The main focus is on cardiovascular, CNS, GI/metabolism and hospital products. More
AstraZeneca
Is committed to building on success, and the continued in-licensing of products and technologies is an acknowledged strategic priority More
SPEEDEL Pharma
Speedel Holding AG is a Swiss-based drug development company focused on the development of pharmaceuticals that address cardiovascular and metabolic diseases. More
Schwarz Pharma
"We Have New Ideas" Schwarz Pharma USA is experiencing explosive growth in the U.S. We are aggressively seeking in-licensing opportunities in CNS, GI, Cardiovascular and Urology markets More
Boehringer Ingelheim
We make your product a success - Boehringer Ingelheim provides highly attentive partnering that ensures enhanced value in all activities to fulfill your aspirations. More
Italfarmaco
More
Displaying 1..10 of 15 - per page Next page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Cardiovascular and metabolic market overview forecast model
Jan 2010 - $15,200
CV & Diabetes Market Forecast
Jan 2009 - $15,200
The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Dec 2009 - 102 pages - $3,500
Menarini: PharmaVitae Profile
Jun 2010 - 48 pages - $5,700
Epidemiology: Hypertension – Rising with increasing obesity and population growth
Oct 2011 - 44 pages - $5,700
Cardiovascular Generic Drugs: Prospects and Opportunities to 2012
Dec 2007 - 186 pages - $3,140
Abbott Laboratories: PharmaVitae Report
May 2011 - 95 pages - $5,700
Cardiovascular Drug Discoveries 2008
Apr 2008 - 314 pages - $3,140
Medtronic Enters into Licensing Agreement with AGA Medical Holdings: A Move to Benefit from Huge Market Opportunity in Structural Heart Defects and Vascular Abnormalities
Jul 2010 - 6 pages - $500
Eli Lilly & Co.: PharmaVitae Report
Jun 2011 - 92 pages - $5,700
More Related Market Research Reports >>>

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us